Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Total Current Liabilities: 2010-2024

Historic Total Current Liabilities for Vanda Pharmaceuticals (VNDA) over the last 15 years, with Dec 2024 value amounting to $100.0 million.

  • Vanda Pharmaceuticals' Total Current Liabilities rose 32.30% to $117.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $117.9 million, marking a year-over-year increase of 32.30%. This contributed to the annual value of $100.0 million for FY2024, which is 14.01% up from last year.
  • Per Vanda Pharmaceuticals' latest filing, its Total Current Liabilities stood at $100.0 million for FY2024, which was up 14.01% from $87.7 million recorded in FY2023.
  • In the past 5 years, Vanda Pharmaceuticals' Total Current Liabilities ranged from a high of $100.0 million in FY2024 and a low of $65.9 million during FY2020.
  • Over the past 3 years, Vanda Pharmaceuticals' median Total Current Liabilities value was $91.4 million (recorded in 2022), while the average stood at $93.0 million.
  • In the last 5 years, Vanda Pharmaceuticals' Total Current Liabilities rose by 22.87% in 2022 and then declined by 4.09% in 2023.
  • Yearly analysis of 5 years shows Vanda Pharmaceuticals' Total Current Liabilities stood at $65.9 million in 2020, then climbed by 12.87% to $74.4 million in 2021, then rose by 22.87% to $91.4 million in 2022, then fell by 4.09% to $87.7 million in 2023, then climbed by 14.01% to $100.0 million in 2024.